Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT MCC Vaccine in PD-L1 Refractory Merkel Cell Carcinoma
NCT03167164Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Fc-Fusion Proteins, Cancer Vaccines, Gene Editing
01
Overview
Phase 2, open-label, single-arm trial of nogapendekin alfa inbakicept, ETBX-051, ETBX-061, gi-6301 and haNK in Merkel cell carcinoma (MCC), sponsored by ImmunityBio, Inc. Primary endpoints: Incidence of treatment-emergent Adverse Events and Serious Adverse Events at 1 year, Objective Response Rate by RECIST Version 1.1 at 1 year and 1 more. Planned start Dec 2017; status: withdrawn.
02
Drugs
nogapendekin alfa inbakiceptETBX-051ETBX-061gi-6301haNK
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03167164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167164.